The activity of MMP-2 and MMP-9 in serum or plasma, measured by gelatine zymography, has been shown to distinguish between breast cancer subclassification and various risk factors, predict lymph node metastasis, and evaluate treatment response in breast cancer patients. This evidence concerns the gene MMP9 and metastatic malignant neoplasm in the lymph nodes.